Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EN-MARK study of trastuzumab deruxtecan as third-line therapy in HER2-positive advanced or recurrent gastric cancer
jRCTs031240055Active, not recruiting
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- May 2024
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Open-label trial of trastuzumab deruxtecan in gastric cancer (GC) and gastroesophageal junction adenocarcinoma (2 cohorts), sponsored by Daiichi Sankyo Co., Ltd. Primary endpoint: Objective response rate. Started May 2024; status: active, not recruiting.
02
Drugs
trastuzumab deruxtecan
03
Conditions
gastric cancer (GC)gastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on jRCTs031240055.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031240055.